EUVIMEDEUVIMED entdecken
Crossref

Identification of unique immune response expression profiles to SARS-CoV-2 in non-small cell lung cancer using systems immunology approach

Saba Al Heialy, Mahmood Yaseen Hachim, Ibrahim Yaseen Hachim, Rifat Hamoudi, Qutayba Hamid

Advances in Biomedical and Health Sciences · 2022

DOI: 10.4103/abhs.abhs_12_22 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Biomedical and Health Sciences, 2022. Verfasst von Saba Al Heialy und 4 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

COVID-19 severity and mortality are higher in patients with lung cancer due to pulmonary complications. Understanding the mechanisms of SARS-COV-2 effect on lung cancer cells in comparison to healthy lung cells can improve our knowledge of the disease biology to discover new therapeutic targets with the aim of improving the management protocols.

Methods

We aimed to investigate the immune response signature generated from COVID-19-infected NSCLC patients and compare with noninfected patients. To achieve this, publicly available transcriptomic data of lung adenocarcinoma cancer cells A549 versus healthy lung epithelium which were SARS-COV-2-infected and mock-infected were retrieved and reanalyzed to identify differentially expressed genes (DEGs) that are dysregulated in SARS-COV-2-infected A549. Identified genes were explored for enriched pathways and further validated in silico for their expression in larger NSCLC lung samples. C57BL/6J mice infected with MA15 (mouse-adapted SARS-CoV) were used to confirm the findings.

Results

A total of 7852 DEGs were identified between A549 (mock and SARS-COV-2 infected) compared to healthy epithelial cells (mock and SARS-COV-2 infected). On the contrary, 142 genes were DEGs between all mocked-infected cells (healthy and cancer) versus SARS-COV-2 infected (healthy and cancer). Those 142 genes were intersected with DEGs from the first step and were shown to be involved in cytokine-mediated signaling pathway and lymphocyte activation. A549-infected cells upregulated ( IL11, RBCK1, CEBPD, EBI3, and ISG15 ) to a higher proportion but downregulated RELB compared to the healthy epithelium. Most of the genes ( Nr1h4, Ebi3, Snai2, IL2rb, IL11, Clec4e, Cebpd , and Relb ) were differentially expressed in the lung of infected mice. In silico validation confirm that IL11 expression is higher in lung adenocarcinoma compared to healthy controls. COVID-19 infection in NSCLC patients lead to the activation of specific cytokines.

Conclusions

Our analysis showed IL11 to be the most differentially expressed between cancer and non-cancer patients and was associated with poor prognosis suggesting that COVID-19 infection in cancer patients leads to the synergistic increase in expression of CD4+ T cells, M1 macrophages, and follicular helper T cells.

Zitieren

APA

Heialy, S. A., Hachim, M. Y., Hachim, I. Y., Hamoudi, R., & Hamid, Q. (2022). Identification of unique immune response expression profiles to SARS-CoV-2 in non-small cell lung cancer using systems immunology approach. Advances in Biomedical and Health Sciences. https://doi.org/10.4103/abhs.abhs_12_22

Vancouver

Heialy SA, Hachim MY, Hachim IY, Hamoudi R, Hamid Q. Identification of unique immune response expression profiles to SARS-CoV-2 in non-small cell lung cancer using systems immunology approach. Advances in Biomedical and Health Sciences. 2022. doi:10.4103/abhs.abhs_12_22

BibTeX
@article{Heialy2022,
  author = {Heialy, Saba Al and Hachim, Mahmood Yaseen and Hachim, Ibrahim Yaseen and Hamoudi, Rifat and Hamid, Qutayba},
  title = {Identification of unique immune response expression profiles to SARS-CoV-2 in non-small cell lung cancer using systems immunology approach},
  journal = {Advances in Biomedical and Health Sciences},
  year = {2022},
  doi = {10.4103/abhs.abhs_12_22}
}
Kostenlos starten →